biostudies-literatureDocherty KFBritish Heart FoundationNIDDK NIH HHS1298-1305https://www.ebi.ac.uk/biostudies/studies/S-EPMC8576587biostudies-literatureUnknown6(11)<h4>Importance</h4>Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransporter 2 inhibitors a helpful addition to clinical trial results when communicating the benefits of this class of drug to patients.<h4>Objective</h4>To estimate the projected long-term treatment effects of dapagliflozin in patients with HFrEF over the duration of a patient's lifetime.<h4>Design, setting, and participants</h4>Exploratory analysis was performed of Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF), a phase 3 randomized, placebo-controlled clinical trial conducted at 410 sites in 20 countries. Patients JAMA cardiologyExtrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.PMC8576587P30 DK045735RE/18/6/34217Ince CMahapekar MSaito KPoirier PKarageorgiev DMohri MVyselaar JFairman ESeki KKitakaze MHiroi SKosiborod MNAntalik LRupka DLangkilde AMVan Eck JJapp ANunohiro TUchida ITeel JMoritani KAkinboboye OHashimoto TJarai ZAlbisu JTakase HKopylov PMalek IHickey GSlovenska MAizenberg DTschope DKatova TMasszi GKuramochi TFulop PMajercak ISpasova NTakeyasu NMahal SDong WDong YFoley BPawlowicz LNguyen Vinh PO'Meara EHaddad TKolomanov BDong JGarcia Brasca DLieber IAnzai TYounis LArif AKothiwale VMartinez DBotushanov NGenth-Zotz SFranchi FLiu JAksentiev SLiu MLiu PVizel SNischik RZoet Nugteren STomasova LEzhov APesant YWeiss SPandey ANagashima HVasconcellos ESala JAl-Zoebi ARobles De Medina RBennett MHarada KSassone STereshchenko SSyed FMooe TMirekBryniarska EOnishi YVenugopal CGuo XLiang YSchou MCostard-Jackle AHajek PShah KPham VMckelvie RJhund PKucera DInzucchi SEFujimoto NNani SMomiyama YHowlett JLuquez HLo EFujimoto KNishino MDesai ASolomon SDKimura AClaggett BPoor FBernstein MKiyosue ASingal DVishneva ESjostrand MKazemi NBengtsson OManenti EPerna EKuwahara KBelohlavek JPaolino BKorzeniak RSelecky JNilk RChang HMacek VChang KDeMets DLKiraly CKomiyama NBerk MIzzo JHan BPeng DLondono JDocherty KFFu LSudnik WParaschos AMercau GLeaes PLampart JGreene TPetrie MFujii KPaltsman ZUdgire PGe JVladeva SIvanova YSchmidt EChopra VSumii KLang CSaraiva JVan Hessen MMody FPimentel PPetrie COkumura YSmik RYao LMariankowski RKomura YNoori EBugan VFukui KBusak LSabatine MSHirohata APonikowski PNajenson MTokmakova MJardula MFong PTakahashi WProkopczuk JDAPA-HF Investigators and CommitteesBellersen LTakahashi NLevinson LSpinarova LConstance CGu YWitek RHotchkiss DSchabauer AHove JSosa Liprandi AOgunniyi MMatsuoka SMayer OKrcova EGogov AArakawa TLin TFlorea VLin XKawamura RReis GColombo Berra FStephan URossi PVidebæk LMaia LKokane HAsakura MRaev DNikfarjam ACaruso GPatel JAvramov DInoue SMcMurray JJVKollarova DRunev NMiekus PMihov AGalyavich ANicolau JCHershson ADo HZaidman CWilke ASandhu MNasser-Sharif FShilko JLin LJaffrani NCha JNierop PMerkely BMeno HNagy LHernandes MZhao QDe Boer RCimato TPereira ATalavera MHigashiue SVinanska DWeigmann ISugino HHamroff GMaung TZChiang CEVijayaraghavan RLederman SAzzari FBertolet BTakagi YSwart HLjungman CHedman ADukat AGupta DCluigt NUeno HMehta SManshadi RMehta VCastriz JPhaneuf DChompalova BKostis JMilanova MLewis TLi XHominal MLi YLi ZWada AJhund PSDe Nooijer CRamanathan KDzhaiani NLewis GDincheva ARassi SSuzuki SHayashi YFerreira JPPevzner DSuzuki MChandra LJiang HHisamatsu YIliev NCzigany AYasaka YWakefield PAhuad Guerrero RPursley MPrecoma DEmani SVerma SKasai TSciborski RKhaykin YLindholm CWalsh JUeda YToursarkissian NShih JZhang XKanwar MNeuenschwander FDrelich GClark ATruong BTereschenko SLeslie SJamriskova LPereiro Gonzalez SShinozaki TSzynal SDalcoquio TIskander SKuchar RZheng ZMenon JUchikawa SMaltcev ACarda JSkopek JMurphy CZacharias MFruehling ETsukahara KBohm MEfremov IBhargava VAndrassy PLee RMartinez FAKatayama YIseki HJavier JGarcia Duran RMiklaszewicz BChernyavsky AEgstrup KArouni ATanaka SGardner RTang QChiang CCheng RSpinar JMontana OTomobuchi YHsieh ISotolongo RArantes FBoldueva SNassif MLash JChehayeb RZhou YFernandez AMotyovszki AHuang WGadkari MDeshpande MKoziolova NIlieva KAppel KDrozdz JKazakov AWu LHsia CAl-Joundi BSinha DHuang JKober LWang DWu CGuimaraes FBrown CKarna SAvino DHata YLindmark KDeleon SSimonis GBabapulle MWang ZTsutsui HAnand IHo DErmoshkina LKostenko VKrylova LShibasaki TKellerer MKakuta TNaik ASinha STaborda JSlaby JKadokami TMansour SDiez MNoguchi YJoseph SViera AGislason GTseng WFrench WHartleib MBanerjee SMajul CHiguchi MStaniloae CCursack GNguyen TSong DSawant RSrivastava SGroenemeijer BNguyen HDidenko YHattori EKamiya HKantaros LBorges JOlexa PfalseExtrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.<h4>Importance</h4>Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransporter 2 inhibitors a helpful addition to clinical trial results when communicating the benefits of this class of drug to patients.<h4>Objective</h4>To estimate the projected long-term treatment effects of dapagliflozin in patients with HFrEF over the duration of a patient's lifetime.<h4>Design, setting, and participants</h4>Exploratory analysis was performed of Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF), a phase 3 randomized, placebo-controlled clinical trial conducted at 410 sites in 20 countries. Patients 2021-01-01T00:00:00Z2021 Nov2026-05-09T03:57:12.091Z2022-08-06T22:43:45.29ZS-EPMC85765873431939810.1001/jamacardio.2021.2632